In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
Professor John Zalcberg OAM Australian Clinical Trials Alliance (ACTA) Board Director & former ACTA Board Chair
Shanny Dyer, Chief Executive Officer, ARCS Australia
Leanne Wells, Chief Executive Officer, Consumers Health Forum of Australia
Liz de Somer, Chief Executive Officer Medicines Australia
Ian Burgess, Chief Executive Officer,
Medical Technology Association of Australia
Watch Season 5, Australian Health Journal Episode S5E1
You Might also like
-
Delivering anaesthetic services to countries where surgical services can’t be provided
Dr Wendy Falloon is an Anaesthetist of over 30 years experience and a Fellow of Australian and New Zealand College of Anaesthetists (ANZCA). She studied medicine at the University of Tasmania, and worked in Hobart, Sydney and the Uk while completing her specialist qualifications. Her primary professional focus has always been to deliver the best possible experience of anaesthesia to each and every patient, and for them to know that she sees and values them, and their stories.
Having been born in Africa, she realised even as a child that health and wealth were largely a product of where people happen to be born. This sowed the seed of her ongoing desire to be of help to others in less fortunate circumstances, ultimately leading to her volunteer work with the Mercy Ships charity. This is one of the most fulfilling aspects of her career, and she has volunteered in Africa with Mercy Ships 8 times since 2014.
-
A clinical research career working Sponsor-side, CRO-side to Site-side
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
-
Closing the diagnostic gap in ovarian cancer detection
After 15 years in academia, Associate Professor Michelle Hill founded ProSeek bio to address one of the most urgent challenges in women’s health: closing the diagnostic gap in ovarian cancer.
For too long, women suspected of ovarian cancer have faced an impossible choice — undergo invasive surgery for diagnosis, only for up to 80% of those procedures to reveal no cancer, or delay intervention and risk diagnosis at a later stage when treatment options are fewer and survival outcomes are significantly worse.